Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML

May S.K. Sutherland, PhD, Changpu Yu, Roland B. Walter, MD PhD, Lori Westendorf, John Valliere-Douglass, PhD, Lucy Pan, PhD, Django Sussman, PhD, Martha Anderson, Weiping Zeng, Ivan Stone, Kerry Klussman, Michelle Ulrich, Mechthild Jonas, PhD, Peter Senter, PhD, Jonathan G. Drachman, MD, Dennis Benjamin, PhD

Blood (2015) 126 (23): 330.

https://doi.org/10.1182/blood.V126.23.330.330

Published: 2015

Journal Articles

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

Blood (2013) 122 (8): 1455–1463.

https://doi.org/10.1182/blood-2013-03-491506

Published: 2013

Includes: Supplemental data

Journal Articles

SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML

May S.K. Sutherland, PhD, Roland B. Walter, MD, PhD, Scott C. Jeffrey, PhD, Patrick J. Burke, PhD, Changpu Yu, MD, Kimberly H. Harrington, BS, Ivan Stone, BS, Maureen C. Ryan, PhD, Django Sussman, PhD, Weiping Zeng, MD, Dennis R. Benjamin, PhD, Irwin D. Bernstein, MD, Peter D. Senter, PhD, Jonathan G. Drachman, MD, Julie A. McEarchern, PhD

Blood (2012) 120 (21): 3589.

https://doi.org/10.1182/blood.V120.21.3589.3589

Published: 2012

Journal Articles

Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study.

Edward Agura, MD, Ruben Niesvizky, MD, Jeffrey Matous, MD, Nikhil Munshi, MD, Mohamad Hussein, MD, Ramakrishnan V Parameswaran, MD, Stefano Tarantolo, MD, Nancy C Whiting, PharmD, BCOP, Jonathan G Drachman, MD, Jeffrey A Zonder, MD

Blood (2009) 114 (22): 2870.

https://doi.org/10.1182/blood.V114.22.2870.2870

Published: 2009

Journal Articles

A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.

Andres Forero-Torres, MD, Nancy L Bartlett, MD, Sunita D Nasta, MD, Donald Northfelt, MD, Anne Beaven, MD, Han Myint, FRCP, FRCPath, Nancy C Whiting, PharmD, BCOP, Jonathan G Drachman, MD, Craig H Moskowitz, MD

Blood (2009) 114 (22): 586.

https://doi.org/10.1182/blood.V114.22.586.586

Published: 2009

Journal Articles

Preclinical Analysis of the Combined Activity of SGN-40, Anti-CD40 Monoclonal Antibody, with Rituximab in Non-Hodgkin Lymphoma.

Timothy S. Lewis, Renee S. McCormick, Julie A. McEarchern, Kim Kissler, Ivan J. Stone, Hans-Peter Gerber, Jonathan G. Drachman, Iqbal Grewal, Che-Leung Law

Blood (2008) 112 (11): 1583.

https://doi.org/10.1182/blood.V112.11.1583.1583

Published: 2008

Journal Articles

Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33.

Azra Raza, MD, Joseph G. Jurcic, MD, Gail J. Roboz, MD, Michael Maris, MD, Joseph Stephenson, MD, Brent L. Wood, MD, Bhaskar Rege, PhD, Laurie E. Grove, PA-C, Jonathan G. Drachman, MD, Eric L. Sievers, MD

Blood (2007) 110 (11): 159.

https://doi.org/10.1182/blood.V110.11.159.159

Published: 2007

Journal Articles

The Humanized Anti-CD40 Monoclonal Antibody, SGN-40, Potentiates Chemotherapy Regimens in NHL Xenograft Models Via Pro-Apoptotic Signaling.

Timothy S. Lewis, PhD, Renee S. McCormick, B.S., Kim Kissler, B.S., Ivan J. Stone, B.S., Mechthild Jonas, Ph.D., May S.K. Sutherland, Ph.D., Hans-Peter Gerber, Ph.D., Jonathan G. Drachman, M.D., Iqbal S. Grewal, Ph.D., Che-Leung Law, Ph.D.

Blood (2007) 110 (11): 2342.

https://doi.org/10.1182/blood.V110.11.2342.2342

Published: 2007

Journal Articles

Results of a Phase I Trial of SGN-40 (Anti-huCD40 mAb) in Patients with Relapsed Multiple Myeloma.

Mohamad A. Hussein, MD, James R. Berenson, MD, Ruben Niesvizky, MD, Nikhil C. Munshi, MD, Jeffrey Matous, MD, Kate Harrop, BA, Jonathan G. Drachman, MD

Blood (2006) 108 (11): 3576.

https://doi.org/10.1182/blood.V108.11.3576.3576

Published: 2006

Journal Articles

SGN-33 Modulates Cytokine and Chemokine Production by Activated Monocytes and Macrophages.

May S.K. Sutherland, PhD, Timothy S. Lewis, PhD, Changpu Yu, MD, Julie A. McEarchern, PhD, Jonathan G. Drachman, MD, Eric L. Sievers, MD, Iqbal S. Grewal, PhD, Che-Leung Law, PhD

Blood (2006) 108 (11): 1995.

https://doi.org/10.1182/blood.V108.11.1995.1995

Published: 2006

Journal Articles

Increased Dose Intensity of SGN-33, a Humanized Monoclonal Antibody Targeting CD33, Is Active and Well-Tolerated in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Azra Raza, MD, Joseph G. Jurcic, MD, Gail J. Roboz, MD, Joseph J. Stephenson, MD, Mark U. Rarick, MD, Brent L. Wood, MD, Laurie E. Grove, PA-C, Eric L. Sievers, MD, Jonathan G. Drachman, MD

Blood (2006) 108 (11): 4568.

https://doi.org/10.1182/blood.V108.11.4568.4568

Published: 2006

Journal Articles

The Humanized Anti-CD40 Antibody SGN-40 Inhibits Tumor Growth in LAGκ-1A, a CD40 + Mouse Model of Human Multiple Myeloma.

Richard A. Campbell, Melinda S. Gordon, PhD, Eric Sanchez, Haiming Chen, MD, PhD, Lauren Turker, Olivia Trac, Mingjie Li, Shen Pang, PhD, Benjamin Bonavida, PhD, Jonathan Said, MD, Jonathan G. Drachman, MD, James R. Berenson, MD

Blood (2006) 108 (11): 3506.

https://doi.org/10.1182/blood.V108.11.3506.3506

Published: 2006

Journal Articles

SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma: Evidence of Antitumor Activity from a Phase I Study.

Ranjana Advani, MD, Andres Forero-Torres, MD, Richard R. Furman, MD, Joseph D. Rosenblatt, MD, Anas Younes, MD, Brooke Shankles, MA, Kate Harrop, BA, Jonathan G. Drachman, MD

Blood (2006) 108 (11): 695.

https://doi.org/10.1182/blood.V108.11.695.695

Published: 2006

Journal Articles

The Humanized Anti-CD40 Antibody, SGN-40, Promotes Apoptosis Signaling and Is Effective in Combination with Standard Therapies in Lymphoma Xenograft Models.

Timothy S. Lewis, PhD, May S.K. Sutherland, Ph.D., Mechthild Jonas, Ph.D., Charles G. Cerveny, M.S., Renee McCormick, B.S., Alan F. Wahl, Ph.D., Jonathan G. Drachman, M.D., Iqbal S. Grewal, Ph.D., Che-Leung Law, Ph.D.

Blood (2006) 108 (11): 2499.

https://doi.org/10.1182/blood.V108.11.2499.2499

Published: 2006

Journal Articles

A Phase I Humanized Anti-CD40 Monoclonal Antibody (SGN-40) in Patients with Multiple Myeloma.

Mohamad A. Hussein, MD, James R. Berenson, MD, Ruben Niesvizky, MD, Nikhil C. Munshi, MD, Kate L. Harrop, Michael McDonald, MRCP, Jonathan G. Drachman, MD

Blood (2005) 106 (11): 2572.

https://doi.org/10.1182/blood.V106.11.2572.2572

Published: 2005

Journal Articles

A Phase I Study of Humanized Anti-CD40 Immunotherapy with SGN-40 in Non-Hodgkin’s Lymphoma.

Ranjana H. Advani, MD, Richard R. Furman, MD, Joseph D. Rosenblatt, MD, Anas Younes, MD, Andres Forero-Torres, MD, Kate L. Harrop, Karen T. Baumgartner, Michael McDonald, MRCP, Jonathan G. Drachman, MD

Blood (2005) 106 (11): 1504.

https://doi.org/10.1182/blood.V106.11.1504.1504

Published: 2005

Journal Articles

Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation

Paula G. Heller, Ana C. Glembotsky, Manish J. Gandhi, Carrie L. Cummings, Carlos J. Pirola, Rosana F. Marta, Laura I. Kornblihtt, Jonathan G. Drachman, Felisa C. Molinas

Blood (2005) 105 (12): 4664–4670.

https://doi.org/10.1182/blood-2005-01-0050

Published: 2005

Journal Articles

Induction of polyploidization in leukemic cell lines and primary bone marrow by Src kinase inhibitor SU6656

Brian J. Lannutti, Noel Blake, Manish J. Gandhi, Jo Anna Reems, Jonathan G. Drachman

Blood (2005) 105 (10): 3875–3878.

https://doi.org/10.1182/blood-2004-10-3934

Published: 2005

Journal Articles

Induction of Polyploidization in Leukemic Cell Lines and Primary Bone Marrow by Src Kinase Inhibitor SU6656.

Brian J. Lannutti, PhD, Jennifer N. Minear, BS, Noel Blake, BS, Jonathan G. Drachman, MD

Blood (2004) 104 (11): 2918.

https://doi.org/10.1182/blood.V104.11.2918.2918

Published: 2004

Journal Articles

Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of hematopoietic cell lines and primary megakaryocytic progenitors

Brian J. Lannutti, Jonathan G. Drachman

Blood (2004) 103 (10): 3736–3743.

https://doi.org/10.1182/blood-2003-10-3566

Published: 2004

NARROW

SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML

Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study.

A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.

Preclinical Analysis of the Combined Activity of SGN-40, Anti-CD40 Monoclonal Antibody, with Rituximab in Non-Hodgkin Lymphoma.

Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33.

The Humanized Anti-CD40 Monoclonal Antibody, SGN-40, Potentiates Chemotherapy Regimens in NHL Xenograft Models Via Pro-Apoptotic Signaling.

Results of a Phase I Trial of SGN-40 (Anti-huCD40 mAb) in Patients with Relapsed Multiple Myeloma.

SGN-33 Modulates Cytokine and Chemokine Production by Activated Monocytes and Macrophages.

Increased Dose Intensity of SGN-33, a Humanized Monoclonal Antibody Targeting CD33, Is Active and Well-Tolerated in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

The Humanized Anti-CD40 Antibody SGN-40 Inhibits Tumor Growth in LAGκ-1A, a CD40 + Mouse Model of Human Multiple Myeloma.

SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma: Evidence of Antitumor Activity from a Phase I Study.

The Humanized Anti-CD40 Antibody, SGN-40, Promotes Apoptosis Signaling and Is Effective in Combination with Standard Therapies in Lymphoma Xenograft Models.

A Phase I Humanized Anti-CD40 Monoclonal Antibody (SGN-40) in Patients with Multiple Myeloma.

A Phase I Study of Humanized Anti-CD40 Immunotherapy with SGN-40 in Non-Hodgkin’s Lymphoma.

Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation

Induction of polyploidization in leukemic cell lines and primary bone marrow by Src kinase inhibitor SU6656

Induction of Polyploidization in Leukemic Cell Lines and Primary Bone Marrow by Src Kinase Inhibitor SU6656.

Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of hematopoietic cell lines and primary megakaryocytic progenitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only